Abeona Therapeutics (ABEO) Competitors $5.18 +0.04 (+0.78%) As of 12:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ABEO vs. COGT, ABCL, PAHC, NUVB, AVBP, TYRA, CDMO, SEPN, AVDL, and PRTAShould you be buying Abeona Therapeutics stock or one of its competitors? The main competitors of Abeona Therapeutics include Cogent Biosciences (COGT), AbCellera Biologics (ABCL), Phibro Animal Health (PAHC), Nuvation Bio (NUVB), ArriVent BioPharma (AVBP), Tyra Biosciences (TYRA), Avid Bioservices (CDMO), Septerna (SEPN), Avadel Pharmaceuticals (AVDL), and Prothena (PRTA). These companies are all part of the "pharmaceutical preparations" industry. Abeona Therapeutics vs. Cogent Biosciences AbCellera Biologics Phibro Animal Health Nuvation Bio ArriVent BioPharma Tyra Biosciences Avid Bioservices Septerna Avadel Pharmaceuticals Prothena Cogent Biosciences (NASDAQ:COGT) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, community ranking, earnings and institutional ownership. Do analysts rate COGT or ABEO? Cogent Biosciences currently has a consensus price target of $14.33, suggesting a potential upside of 77.17%. Abeona Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 247.16%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than Cogent Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cogent Biosciences 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57Abeona Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, COGT or ABEO? Abeona Therapeutics has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCogent BiosciencesN/AN/A-$192.41M-$2.48-3.26Abeona Therapeutics$3.50M64.40-$54.19M-$2.69-1.93 Does the media favor COGT or ABEO? In the previous week, Cogent Biosciences had 3 more articles in the media than Abeona Therapeutics. MarketBeat recorded 7 mentions for Cogent Biosciences and 4 mentions for Abeona Therapeutics. Abeona Therapeutics' average media sentiment score of 0.92 beat Cogent Biosciences' score of 0.60 indicating that Abeona Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Abeona Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is COGT or ABEO more profitable? Cogent Biosciences' return on equity of -112.55% beat Abeona Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cogent BiosciencesN/A -112.55% -60.44% Abeona Therapeutics N/A -203.27%-64.56% Does the MarketBeat Community favor COGT or ABEO? Abeona Therapeutics received 234 more outperform votes than Cogent Biosciences when rated by MarketBeat users. However, 70.59% of users gave Cogent Biosciences an outperform vote while only 69.69% of users gave Abeona Therapeutics an outperform vote. CompanyUnderperformOutperformCogent BiosciencesOutperform Votes28870.59% Underperform Votes12029.41% Abeona TherapeuticsOutperform Votes52269.69% Underperform Votes22730.31% Which has more risk & volatility, COGT or ABEO? Cogent Biosciences has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Do institutionals & insiders have more ownership in COGT or ABEO? 80.6% of Abeona Therapeutics shares are owned by institutional investors. 5.9% of Cogent Biosciences shares are owned by insiders. Comparatively, 5.4% of Abeona Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryCogent Biosciences and Abeona Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Abeona Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABEO vs. The Competition Export to ExcelMetricAbeona TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$225.62M$6.61B$5.45B$9.16BDividend YieldN/A2.94%5.36%3.97%P/E RatioN/A4.2656.3613.19Price / Sales63.84332.671,313.9479.68Price / CashN/A66.9144.6537.72Price / Book8.575.105.004.72Net Income-$54.19M$154.66M$117.81M$224.61M7 Day Performance-1.91%1.67%2.07%1.41%1 Month Performance-9.67%0.75%3.46%4.13%1 Year Performance5.54%4.41%25.40%21.37% Abeona Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABEOAbeona Therapeutics3.8159 of 5 stars$5.18+0.8%$18.00+247.5%+1.2%$225.61M$3.50M-1.93N/ANews CoverageCOGTCogent Biosciences1.6611 of 5 stars$8.03-1.2%$14.33+78.5%+74.5%$886.99MN/A-3.2480ABCLAbCellera Biologics2.7514 of 5 stars$2.97+1.0%$8.33+180.6%-35.9%$877.25M$38.03M-4.87500PAHCPhibro Animal Health4.1272 of 5 stars$20.82-0.5%$20.50-1.5%+94.6%$843.27M$1.05B48.421,940NUVBNuvation Bio2.2162 of 5 stars$2.51-1.4%$7.40+195.4%+76.9%$843.11MN/A-1.1560Analyst ForecastGap DownAVBPArriVent BioPharma1.2949 of 5 stars$24.41-0.3%$36.80+50.8%N/A$822.62MN/A0.0040Analyst ForecastNews CoverageTYRATyra Biosciences2.6855 of 5 stars$16.19+0.2%$30.50+88.4%+19.4%$819.21MN/A-10.0620Insider TradeCDMOAvid Bioservices2.2928 of 5 stars$12.39+0.1%$12.25-1.1%+88.9%$792.50M$150.45M-5.18320SEPNSepterna2.2166 of 5 stars$16.89-0.5%$43.67+158.5%N/A$749.92MN/A0.00N/AAnalyst RevisionNews CoverageAVDLAvadel Pharmaceuticals3.5174 of 5 stars$7.75-3.1%$21.00+171.0%-46.3%$746.79M$27.96M-9.8170PRTAProthena2.6858 of 5 stars$13.77+4.5%$46.50+237.7%-57.6%$740.96M$91.37M-5.55130Analyst RevisionPositive News Related Companies and Tools Related Companies Cogent Biosciences Alternatives AbCellera Biologics Alternatives Phibro Animal Health Alternatives Nuvation Bio Alternatives ArriVent BioPharma Alternatives Tyra Biosciences Alternatives Avid Bioservices Alternatives Septerna Alternatives Avadel Pharmaceuticals Alternatives Prothena Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ABEO) was last updated on 1/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Abeona Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
